IL-17A is an important cytokine in intestinal inflammation. However, anti-IL-17A therapy does not improve clinical outcomes in patients with Crohn's disease. We aimed to evaluate the role of RORγt + innate lymphoid cells (ILCs) in murine colitis models in the absence of IL-17A. An acute colitis model was induced with either dextran sulfate sodium (DSS) or trinitrobenzenesulfonic acid (TNBS) and a chronic colitis model was induced by CD4 + CD45RB hi T cell transfer from either wild-type C57BL/6 or Il17a −/− mice. An anti-IL-17A antibody, secukinumab, was also used to inhibit IL-17A function in the colitis model. Flow cytometry was performed to analyze the population of RORγt + iLcs in the colonic lamina propria of mice with chronic colitis. Acute intestinal inflammation due to DSS and TNBS was attenuated in IL-17A knockout mice, whereas chronic colitis was not relieved by T cell transfer from Il17a −/− mice (% of original body weight: wild-type mice vs. Il17a −/− mice, 81.9% vs. 82.2%; P = 0.922). However, the mean proportion of Lin-RoRγt + lymphocytes was higher after T cell transfer from Il17a −/− mice than that after T cell transfer from wild-type mice (28.8% vs. 18.5%). The proportion of Lin-RoRγt + was also increased in Rag2 −/− mice that received T cell transfer from wild-type mice when anti-IL-17A antibody was administered (31.7%). Additionally, Il6 and Il22 tended to be highly expressed after T cell transfer from Il17a −/− mice. In conclusion, RORγt + ILCs may have an important role in the pathogenesis of chronic colitis in the absence of IL-17A. Blocking the function of IL-17A may upregulate Il6 and recruit RoRγt + ILCs in chronic colitis, thereby upregulating IL-22 and worsening the clinical outcomes of patients with Crohn's disease. In patients with Crohn's disease, IL-17A-producing cells are highly prevalent in the intestinal mucosa, and intestinal mucosal cells exhibit high transcript expression levels of IL-17A 1,2. Fecal IL-17A has also been observed in patients with active Crohn's disease. Based on these findings, anti-IL-17A therapy would be expected to be effective in treating patients with Crohn's disease 3. However, initial trials of anti-IL-17A therapy for Crohn's disease has yielded disappointing results. In a clinical trial of anti-IL-17A antibody, secukinumab, for Crohn's disease did not improve symptoms 3. Moreover, severe adverse events, including cases of Crohn's disease worsening further, occurred in the secukinumab group. A phase II trial of brodalumab, an IL-17R blocker, also showed no benefit for Crohn's disease compared to placebo 4. In the context of the successful outcomes of secukinumab treatment for psoriasis and rheumatoid arthritis 5-7 , the lack of efficacy for secukinumab in treating Crohn's disease was highly disappointing. Unlike the negative results of anti-IL-17A therapy, treatment with IL-12/IL-23 antagonists or selective IL-23 antagonists, including ustekinumab, risankizumab, and brazikumab, which block the upstream pathway of IL-17, are effective against Crohn's disea...